122 related articles for article (PubMed ID: 23710916)
1. [Clinicopathologic features and immunohistochemistry of the basal-like subtype of invasive breast carcinoma].
Liu LP; Bai J; Wei Y; Qi XD; Si TC; Li W; Pan H
Zhonghua Bing Li Xue Za Zhi; 2013 Feb; 42(2):101-5. PubMed ID: 23710916
[TBL] [Abstract][Full Text] [Related]
2. [Clinicopathologic study of centrally necrotizing carcinoma of breast].
Yu L; Yang WT; Cai X; Lu HF; Fan YZ; Shi DR
Zhonghua Bing Li Xue Za Zhi; 2009 Oct; 38(10):657-62. PubMed ID: 20078968
[TBL] [Abstract][Full Text] [Related]
3. [Clinicopathologic features and prognostic significance of basal-like breast cancer].
Liu H; Fan QH; Li X; Liu GZ
Zhonghua Bing Li Xue Za Zhi; 2009 May; 38(5):316-22. PubMed ID: 19575874
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathologic features of breast carcinomas classified by biomarkers and correlation with microvessel density and VEGF expression: a study from Thailand.
Chuangsuwanich T; Pongpruttipan T; O-Charoenrat P; Komoltri C; Watcharahirun S; Sa-Nguanraksa D
Asian Pac J Cancer Prev; 2014; 15(3):1187-92. PubMed ID: 24606439
[TBL] [Abstract][Full Text] [Related]
5. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
Tsutsumi Y
Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
[TBL] [Abstract][Full Text] [Related]
6. [Morphological features of basal-like subtype invasive carcinoma of breast].
Gao LX; Yang GZ; Ding HY; Li L
Zhonghua Bing Li Xue Za Zhi; 2008 Feb; 37(2):83-7. PubMed ID: 18681317
[TBL] [Abstract][Full Text] [Related]
7. [Roles of immunohistochemistry in prognostic assessment of basal-like breast cancer].
Liu H; Fan QH; Zhang ZH; Li X; Yu HP; Liu GZ; Meng FQ
Zhonghua Bing Li Xue Za Zhi; 2009 Jan; 38(1):23-8. PubMed ID: 19489221
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
[TBL] [Abstract][Full Text] [Related]
9. [Relationship between breast cancer molecular subtypes with clinicopathological characteristics and prognosis].
Lin M; Chen ZQ; Bao Y; Li Q; Du ZG; Xu ZD; Tang F
Zhonghua Bing Li Xue Za Zhi; 2010 Jun; 39(6):372-6. PubMed ID: 21055152
[TBL] [Abstract][Full Text] [Related]
10. Inference of the Basal epithelial phenotype in breast carcinoma from differential marker expression, using tissue microarrays in triple negative breast cancer and women younger than 35.
Nassar A; Sussman ZM; Lawson D; Cohen C
Breast J; 2012 Sep; 18(5):399-405. PubMed ID: 22882580
[TBL] [Abstract][Full Text] [Related]
11. [Research progress on basal-like breast cancer].
Chen LY; Chen HF
Ai Zheng; 2008 May; 27(5):555-8. PubMed ID: 18479610
[TBL] [Abstract][Full Text] [Related]
12. [Expression of CK5/6 and CK17 and its correlation with prognosis of triple-negative breast cancer patients].
Liu ZB; Wu J; Ping B; Feng LQ; Shen ZZ; Shao ZM
Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):610-4. PubMed ID: 19102940
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical analysis of ER, PR, Her2 and CK5/6 in infiltrative breast carcinomas in Indian patients.
Munjal K; Ambaye A; Evans MF; Mitchell J; Nandedkar S; Cooper K
Asian Pac J Cancer Prev; 2009; 10(5):773-8. PubMed ID: 20104967
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathologic features of molecular subtypes of triple negative breast cancer based on immunohistochemical markers.
Choi J; Jung WH; Koo JS
Histol Histopathol; 2012 Nov; 27(11):1481-93. PubMed ID: 23018247
[TBL] [Abstract][Full Text] [Related]
15. Male breast cancer: immunohistochemical subtypes and clinical outcome characterization.
Sánchez-Muñoz A; Román-Jobacho A; Pérez-Villa L; Sánchez-Rovira P; Miramón J; Pérez D; Sáez MI; de Luque V; Medina L; Ramírez-Tortosa CL; Vicioso L; Medina JA; Ribelles N; Alba E
Oncology; 2012; 83(4):228-33. PubMed ID: 22907070
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneity of luminal breast cancer characterised by immunohistochemical expression of basal markers.
Sung H; Garcia-Closas M; Chang-Claude J; Blows FM; Ali HR; Figueroa J; Nevanlinna H; Fagerholm R; Heikkilä P; Blomqvist C; Giles GG; Milne RL; Southey MC; McLean C; Mannermaa A; Kosma VM; Kataja V; Sironen R; Couch FJ; Olson JE; Hallberg E; Olswold C; Cox A; Cross SS; Kraft P; Tamimi RM; Eliassen AH; Schmidt MK; Bolla MK; Wang Q; Easton D; Howat WJ; Coulson P; Pharoah PD; Sherman ME; Yang XR
Br J Cancer; 2016 Feb; 114(3):298-304. PubMed ID: 26679376
[TBL] [Abstract][Full Text] [Related]
17. Basal-like breast cancer defined by FOXC1 expression offers superior prognostic value: a retrospective immunohistochemical study.
Ray PS; Bagaria SP; Wang J; Shamonki JM; Ye X; Sim MS; Steen S; Qu Y; Cui X; Giuliano AE
Ann Surg Oncol; 2011 Dec; 18(13):3839-47. PubMed ID: 21424368
[TBL] [Abstract][Full Text] [Related]
18. [Value of CK5/6, CK14, ER and PR detection in differential diagnosis of intraductal proliferative lesions of the breast].
Niu F; Wang L; Zhang W; Lyu S; Niu Y
Zhonghua Zhong Liu Za Zhi; 2015 Oct; 37(10):749-52. PubMed ID: 26813593
[TBL] [Abstract][Full Text] [Related]
19. Breast cancer molecular class ERBB2: preponderance of tumors with apocrine differentiation and expression of basal phenotype markers CK5, CK5/6, and EGFR.
Bhargava R; Beriwal S; Striebel JM; Dabbs DJ
Appl Immunohistochem Mol Morphol; 2010 Mar; 18(2):113-8. PubMed ID: 19801938
[TBL] [Abstract][Full Text] [Related]
20. c-Kit expression as a prognostic molecular marker in patients with basal-like breast cancer.
Kashiwagi S; Yashiro M; Takashima T; Aomatsu N; Kawajiri H; Ogawa Y; Onoda N; Ishikawa T; Wakasa K; Hirakawa K
Br J Surg; 2013 Mar; 100(4):490-6. PubMed ID: 23319435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]